Skip to main content
. 2013 Nov 19;8(11):e79843. doi: 10.1371/journal.pone.0079843

Figure 4. Independent validation of the four-gene signature in a large cohort of neuroblastoma patients (SIOPEN/GPOH).

Figure 4

(A) Kaplan–Meier and log-rank analysis for progression-free (PFS) and overall (OS) survival of the SIOPEN/GPOH cohort (discovery set 6): survival of 348 neuroblastoma patients in the 4 quartiles of the signature score. (B) Validation of the signature based on the four-gene PAM classifier. (C) Classification of the SIOPEN stage 4 tumors with MYCN single copy based on the four-gene PAM classifier. (D) Multivariate logistic regression analysis: Odds Ratio and p-values are shown for disease stage (stage 4 vs. other), age (<> 1y), MYCN status, and the four-gene signature score.